Guggenheim Partners

TIS Has Signed Binding Agreement with Marlin Equity Partners to Secure a Majority Growth Investment

Retrieved on: 
Tuesday, March 26, 2024
Growth, CFO, Partnership, Guggenheim Partners, TIS, Treasury, Senior management, B2B, Cryptocurrency

Marlin Equity Partners has signed a binding agreement to acquire a majority stake in Treasury Intelligence Solutions.

Key Points: 
  • Marlin Equity Partners has signed a binding agreement to acquire a majority stake in Treasury Intelligence Solutions.
  • Co-founder Joerg Wiemer, Aquiline Capital Partners LP, and the Management Team retain significant minority positions in the company.
  • BERLIN, Germany, Mar 26, 2024 - (ACN Newswire) - Today, Treasury Intelligence Solutions ("TIS"), a global leader in cloud-native cash management, liquidity and payment solutions, announced that it has signed a binding agreement to secure majority growth investment from Marlin Equity Partners ("Marlin").
  • The investment positions TIS to execute on organic and inorganic strategic initiatives to further serve the Office of the CFO.

NGM Bio Announces Closing of Tender Offer

Retrieved on: 
Friday, April 5, 2024
Atlas, Patient, SAN, NGM, Column, Sub, Expiration, Guggenheim Partners, Therapy, Mergers and acquisitions, TCG, Holding company

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).
  • As of the Expiration Date, a total of 22,323,295 shares of NGM Bio common stock were validly tendered, and not validly withdrawn, representing approximately 27% of the outstanding shares of NGM Bio common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into NGM Bio and all shares of NGM Bio common stock that had not been validly tendered (other than shares held by stockholders who properly demanded appraisal of such shares or shares held by affiliates of TCG and certain other stockholders who agreed to exchange their shares for shares of Parent) were converted into the right to receive the Offer Price (the “Merger”).

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Retrieved on: 
Friday, April 5, 2024
NMIBC, Private, Exercise, Patient, Oppenheimer Holdings, Sale, Public expenditure, Cancer, Trial of the century, Guggenheim Partners, Share (finance), Therapy, Security (finance)

Gross proceeds from the private placement are expected to be approximately $45 million, before deducting expenses.

Key Points: 
  • Gross proceeds from the private placement are expected to be approximately $45 million, before deducting expenses.
  • Proceeds from the private placement, along with existing cash and cash equivalents, are expected to be sufficient to fund the Company’s planned operations into 2026.
  • The Company intends to use the net proceeds from the Private Placement for general corporate and working capital purposes, including funding clinical trials.
  • Guggenheim Securities, LLC acted as lead placement agent and Oppenheimer & Co. acted as a placement agent in the transaction.

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024
Regeneration, Exercise, Exchange, Patient, SAN, Column, Sale, Mortality, LLP, Public expenditure, Security (finance), Cooley LLP, Guggenheim Partners, Crosstalk (biology), P.C, Therapy

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN, SRZNW), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock. If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock. The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.

Key Points: 
  • If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock.
  • The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
  • The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.
  • Guggenheim Securities, LLC is acting as sole placement agent for the private placement and is being advised by Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, Lung cancer, Medical school, Shanghai Jiao Tong University, Carcinoma, Fast track (FDA), Form, Patient, G&A, School, IPO, Hope, Security (finance), Guggenheim Partners, Investment, Platinum, Interim, Genelux Corporation, FDA, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.

Key Points: 
  • – $23.2 million in cash, cash equivalents and short-term investments –
    WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
  • Currently, 21 sites have been activated to enroll patients with additional sites identified and in various stages of activation ( NCT05281471 ).
  • Genelux and our partner Newsoara co-sponsor the trial, which is being conducted by Newsoara in greater China.
  • Cash, cash equivalents and short-term investments were $23.2 million as of December 31, 2023 compared to $0.4 million on December 31, 2022.

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Retrieved on: 
Thursday, March 28, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
  • All shares and pre-funded warrants in the offering are being offered by Praxis.
  • In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

All securities in the offering will be offered by Praxis.

Key Points: 
  • All securities in the offering will be offered by Praxis.
  • Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering.
  • The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
  • The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus.

Guggenheim Investments Ranked Barron’s Best Taxable Bond Fund Family

Retrieved on: 
Monday, March 18, 2024
Guggenheim Partners, Security (finance)

This is the second time in four years that Guggenheim Investments has taken the top slot among Taxable Bond Fund Families.

Key Points: 
  • This is the second time in four years that Guggenheim Investments has taken the top slot among Taxable Bond Fund Families.
  • Guggenheim Investments’ total fixed income mutual fund assets increased over 19 percent in 2023, and generated net sales of $1.6 billion year-to-date through the end of February 2024.
  • “On behalf of our clients, we’re honored to be recognized by Barron’s as top Taxable Bond Fund Family once again this year,” said Dina DiLorenzo, Co-President of Guggenheim Investments.
  • “Stewardship of client trust is paramount to all of us at Guggenheim and Barron’s recognition of Guggenheim serves as further validation of this firmwide commitment.

Rubrik Files Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Monday, April 1, 2024
Technology, Data Management, Security, Deutsche Bank, Wedbush Securities, Citigroup, Exchange, Goldman Sachs, Wells Fargo, Form, Telephone, Sale, Attention, Guggenheim Partners, Prospectus, BMO Capital Markets, KeyBank, Barclays, Security (finance)

Rubrik, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to a proposed initial public offering of its Class A common stock.

Key Points: 
  • Rubrik, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to a proposed initial public offering of its Class A common stock.
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • A registration statement related to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective.
  • These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

Kinbow Acquires Majority Stake in Ashley Stewart, Inc. Expanding Its Commitment to Retail

Retrieved on: 
Monday, April 1, 2024
Fashion, Retail, Guggenheim Partners, Woman, Acquisition

(“Kinbow”), today announced the agreement to acquire the majority stake of Ashley Stewart, Inc. (Ashley Stewart) from ASI Holdco, LLC, the parent company of Ashley Stewart, the leading fashion retailer of apparel, intimates, and accessories for women sizes 10 to 36.

Key Points: 
  • (“Kinbow”), today announced the agreement to acquire the majority stake of Ashley Stewart, Inc. (Ashley Stewart) from ASI Holdco, LLC, the parent company of Ashley Stewart, the leading fashion retailer of apparel, intimates, and accessories for women sizes 10 to 36.
  • This strategic acquisition is designed to further strengthen Kinbow’s growing position in the value fashion retail market.
  • Kinbow plans to continue to operate all of Ashley Stewart’s brick-and-mortar stores and ecommerce business in their current form and keep Ashley Stewart’s management team in place.
  • Kinbow LLC was represented by Norris McLaughlin, P.A., with attorneys Jeffrey K. Cassin , Mariya Gonor , and Samuele Riva leading the transaction.